Here are three things to know.
1. Giapreza is an injection that increases blood pressure in adults experiencing any form of distributive shock, a critical condition in which blood pressure drops so low that vital organs can’t receive enough blood flow to function properly.
2. The FDA warns that Giapreza can cause blood clots, so a prophylactic treatment should be used.
3. La Jolla Pharmaceutical plans to make the drug available to U.S. patients in March 2018, according to Reuters.
More articles on supply chain:
6 must-reads for supply chain leaders this week
France officials fine J&J $30M for allegedly restricting access to generic versions of its pain patch
Pfizer authorizes $10B share buyback
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
